Article Details
Retrieved on: 2021-07-02 15:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Endometrial cancers determined to be dMMR (mismatch repair deficient) by Roche's assay may be eligible for treatment with JEMPERLI (dostarlimab- ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here